Globus Medical (GMED) offers strong growth, solid profitability, and fair valuation, making it an ideal GARP strategy pick for investors seeking balanced returns.
Shares of medical device company Globus Medical (NYSE:GMED)
fell 6.6% in the afternoon session after the unexpected resignation of its President and CEO, Daniel Scavilla.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Globus Medical (NYSE:GMED) is a strong growth stock with solid fundamentals and a potential technical breakout, making it a candidate for investors seeking growth opportunities in the healthcare sector.
Globus Medical (NYSE:GMED) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth in the healthcare sector.
Shareholders of Globus Medical would probably like to forget the past six months even happened. The stock dropped 28.9% and now trades at $58.14. This was partly due to its softer quarterly results and might have investors contemplating their next move.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
Medical device company Globus Medical (NYSE:GMED) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 billion at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP profit of $0.68 per share was 8.6% below analysts’ consensus estimates.
Globus Medical (NYSE:GMED) shows strong growth fundamentals and a technical setup suggesting a potential breakout. The stock combines revenue growth, profitability, and a favorable chart pattern.
GLOBUS MEDICAL (NYSE:GMED) is a strong growth stock with reasonable valuation, solid profitability, and a healthy balance sheet, making it an attractive option for investors seeking growth at a fair price.
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
GLOBUS MEDICAL (NYSE:GMED) offers strong growth potential at a reasonable valuation, backed by solid financial health. A closer look at its fundamentals suggests it could be a compelling pick for growth-oriented investors.
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
